Free Consultation
(310) 207-3233
No Fees Unless We Win
(310) 207-3233
Menu

"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"

Mary Flores
Reviewed
on Google
Read More Reviews

Michael L. Baum

Attorney, Senior Partner

Michael L. Baum is a senior partner of Wisner Baum (formerly Baum Hedlund Aristei & Goldman) based in Los Angeles. For 29 years, Michael was the managing partner of Baum Hedlund until he turned over the reins to R. Brent Wisner at the beginning of 2023.

Under Michael’s stewardship, our firm grew from a small boutique law firm to one of the nation’s leading plaintiffs’ litigation firms that is now known for its cutting-edge, superior legal work. While running Baum Hedlund, the firm’s success in challenging cases and precedent-setting legal rulings has helped shape the law for the benefit of those harmed in commercial transportation accidents and by dangerous pharmaceuticals and consumer products. Michael’s ceaseless advocacy in pharmaceutical and consumer fraud litigation has brought our firm international attention and acclaim.

“When I became an attorney in 1985, we were the new kids on the block. We only had dreams of achieving the success we now enjoy,” Michael Baum says. “Our ethos from the beginning was pure and simple: we wanted to use the law to help people who had been wronged and make the world a better place. As much as we have grown over the years, that philosophy has remained, and out of it grew a culture that has attracted talented lawyers like Brent who share the same mission. He is exactly the kind of lawyer and leader that will take this firm to new heights. Wisner Baum is in good hands.”

Our firm has won billions under Michael’s leadership in consumer fraud and product liability cases against some of the world’s largest pharmaceutical and life sciences corporations, including Bayer Corp. (Monsanto), Eli Lilly, Forest Labs, GlaxoSmithKline, and Pfizer, among many others.

As a sophisticated legal team, the firm has helped uncover harmful drug industry practices, chemical manufacturer misconduct and deceptive marketing schemes which have resulted in groundbreaking verdicts, major consumer safety advocacy and improved drug warning labels.

Michael has also successfully led the firm through thousands of wrongful death and personal injury cases stemming from mass disasters. These include structure fire and wildfire litigation. His experience litigating fire cases began in 1987 when he worked on the Dupont Plaza Hotel arson case, one of the deadliest hotel fires in U.S. history. He also helped litigate hundreds of homeowner and business claims that resulted in lost structures that burned down in Malibu, California as a result of the 2018 Woolsey Fire.

Firm Awards
Profile
  • University of California, Los Angeles School of Law (J.D., 1985)
  • University of California, Los Angeles (B.A., summa cum laude, 1982)
  • U.S. Court of Appeals, First Circuit, 2013
  • U.S. District Court, Eastern District of Wisconsin, 2009
  • U.S. District Court, Western District of New York, 2009
  • U.S. District Court for the Southern District of California, 1999
  • U.S. Court of Appeals, Seventh Circuit, 1997
  • U.S. Court of Appeals, Fourth Circuit, 1996
  • U.S. District Court, Northern District of New York, 1996
  • District of Columbia, 1993
  • U.S. District Court, Northern District of Ohio, 1993
  • U.S. District Court, Western District of Michigan, 1991
  • U.S. Supreme Court, 1991
  • U.S. Court of Appeals, Ninth Circuit, 1990
  • U.S. District Court, Central District of California, 1986
  • U.S. District Court, Eastern District of California, 1989
  • U.S. District Court, Northern District of California, 1989
  • California, 1985
  • The District of Columbia Court of Appeals, 1983
  • Trial Team Member, Pilliod et al., vs Monsanto Company (3rd Roundup cancer verdict $2.055 billion), Oakland, California, 2019
  • Trial Team Member, Hardeman vs Monsanto Company (2nd Roundup cancer verdict $80 million), San Francisco, California, 2019
  • Trial Team Member, Dewayne “Lee” Johnson vs Monsanto Company (1st Roundup cancer verdict $289.2 million), San Francisco, California, 2018
  • Trial Team Member, Wendy B. Dolin vs GlaxoSmithKline LLC (generic Paxil suicide verdict $3 million), Chicago, Illinois, 2017
  • Plaintiffs’ Executive Committee, MDL-2741, In Re: Roundup Products Liability Litigation (U.S. District Court for the Northern District of California), 2016-present
  • Plaintiffs’ Steering Committee, Judicial Council Coordinated Proceedings (JCCP 4696) In re Actos Product Liability Cases, Los Angeles, California, 2012 – 2020
  • Plaintiffs’ Steering Committee, MDL-1574, Paxil Products Liability Litigation
  • Trial Team Member, Consolidated Hemophilia-AIDS Cases, New Orleans, Louisiana, 1999
  • Lead Counsel for 125 Consolidated Complex Biological-Medical Products Liability Cases, New Orleans, Louisiana, 1997-2001
  • Plaintiffs’ Steering Committee, Illinois State Court Proceedings for USAir 427 Aircrash near Aliquippa, Pennsylvania, 1994
  • Trial Team Member, 1997, USAir 1016 Aircrash of Charlotte, North Carolina, 1994
  • Plaintiffs’ Steering Committee, MDL 1041, USAir 1016 Aircrash of Charlotte, North Carolina, 1994
  • Plaintiffs’ Steering Committee, MDL 891, Northwest Airlines Flight 255 Crash, Romulus, Michigan, 1990
  • Trial Team Member, 1991-1992, United Airlines Flight 232 Crash, Sioux City, Iowa, 1989
  • Plaintiffs’ Steering Committee, MDL 817, United Airlines Flight 232 Crash, Sioux City, Iowa, 1989
  • American Association for Justice: Leader’s Forum – Champion
  • Consumer Attorneys Association of Los Angeles
  • Consumer Attorneys of California – President’s Club Benefactor
  • San Francisco Trial Lawyers Association
  • American Association for Justice Conferences
  • AutismOne Conference
  • Children’s Health Defense Conference
  • Consumer Attorneys of California Convention
  • HarrisMartin Conferences
  • HB Litigation Conferences
  • Irving H. Green Memorial Lecture Series: Suing Monsanto: Corporate Accountability in Trial Law, UCLA School of Law, 2021
  • Mass Torts Made Perfect Conferences
  • Santa Monica College, Visiting Lecturer in the Department of Philosophy and Social Sciences
  • Selling Sickness Conferences
  • Ubiquity University
  • University of California, Los Angeles, (UCLA) School of Law, Emmett Institute on Climate Change & the Environment and The Resnick Center for Food Law & Policy
  • University of California, Los Angeles, (UCLA) School of Law, The Irving H. Green Memorial Lecture
  • Yale University, Yale Law School
  • Briefing in Brussels - Attorney Baum, his law partner, Brent Wisner, and two clients, Teri McCall and John Barton, traveled to Brussels by invitation to meet with and brief EU press, lawmakers from Germany and France, and staffers for various Members of European Parliaments (MEPs). They arrived just days before a hearing organized by EU environmental and agricultural committees to discuss their firm’s release of the Monsanto Papers and allegations that Monsanto unduly influenced studies on glyphosate, the active ingredient in Roundup. They warned officials about the cancer risk associated with glyphosate and Roundup. Attorneys Baum and Wisner also sent a letter to EU officials requesting they conduct an official inquiry into Monsanto’s manipulation of science and potential collusion with regulators. Belgium, October 4-5, 2017
  • Published the Monsanto Papers - During the Monsanto Roundup cancer litigation, Michael, his partner, Brent Wisner, and their team, declassified and published internal documents known as the Monsanto Papers, revealing Monsanto’s scientific manipulation to hide the truth about Roundup’s harmful effects. This evidence and the successful plaintiffs verdicts have changed how the world questions the safety of Roundup, resulting in regulatory changes, restrictions and bans of glyphosate across the globe. August 1, 2017 through December 2019
  • Jones v. Monsanto Company, 38 F.4th 693, (C.A.8 Mo. 2022) Civil Rights — Free Speech. Order for cy pres distribution of residual funds, after class-action settlement, was not compelled speech under First Amendment.
  • Painters and Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Company Limited, 520 F.Supp.3d 1258 (C.D.Cal. 2021) Torts — RICO. Class action claims against pharmaceutical companies for violation of Racketeer Influenced and Corrupt Organizations Act were adequately alleged.
  • Painters and Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceuticals Company Limited, 943 F.3d 1243, (C.A.9 Cal. 2019) Torts — RICO. Plaintiffs plausibly alleged element of proximate cause, as required to support civil RICO claim against pharmaceutical company.
  • Painters and Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceuticals Company Limited, 796 Fed.Appx. 919, (C.A.9 Cal. 2019) Commercial Law — Unfair Practices. Consumer sufficiently alleged damages, as required to state Florida Deceptive and Unfair Trade Practices Act claim.
  • In re Celexa and Lexapro Marketing and Sales Practices Litigation, 915 F.3d 1, (C.A.1 (Mass. 2019) Torts — RICO. FDA approval of pharmaceutical manufacturer’s antidepressant did not preclude RICO claims based on manufacturer’s pre-approval “off-label” marketing.
  • Blitz v. Monsanto Company, 317 F.Supp.3d 1042, (W.D.Wis. 2018) Commercial Law — Unfair Practices. Consumer’s state law claims against herbicide manufacturer were not preempted by Federal Insecticide, Fungicide, and Rodenticide Act.
  • Dolin v. GlaxoSmithKline LLC, 269 F.Supp.3d 851, (N.D.Ill. 2017) Products Liability — Warnings. Sufficient evidence supported finding that warnings regarding risk of suicide on antidepressant’s label were inadequate and misleading.
  • Dolin v. SmithKline Beecham Corporation, 62 F.Supp.3d 705, (N.D.Ill. 2014) Health — Drugs. Drug manufacturer’s relation to plaintiff was sufficient to impose reasonable conduct duty, supporting negligence claim related to design and warning.
  • In re Celexa and Lexapro Marketing and Sales Practices Litigation, 769 F.Supp.2d 11, (D.Mass. 2011) Health - Drugs. Fraud claim against pharmaceutical manufacturer was not time-barred.
  • In re Celexa and Lexapro Marketing and Sales Practices Litigation, 751 F.Supp.2d 277, (D.Mass. 2010) Antitrust - Health Care Providers. Allegation that physician was misled by pharmaceutical manufacturer into prescribing drug was sufficient to allege causation.
  • Dorsett v. Sandoz, Inc., 699 F.Supp.2d 1142 (C.D.Cal. 2010) (denying defendants’ preemption motion and holding that both name-brand and generic drug manufacturers have an affirmative duty to issue warnings)
  • Mason v. SmithKline Beecham Corp., 596 F.3d 387 (7th Cir. 2010) (unanimously reversing the trial court’s preemption ruling and allowing plaintiffs’ claims to proceed to a trial on the merits)
  • Collins v. SmithKline Beecham Corp., 2008 WL 744070 (Pa. Ct.Com.Pl. March 11, 2008)
  • Grisham v. Philip Morris USA, 482 F. 3d 1131 (9th Cir. 2007)
  • Grisham v. Philip Morris USA, 40 Cal.4th 623, 151 P.3d 1151, 54 Cal.Rptr.3d 735 (2007)
  • Grisham v. Philip Morris USA, 403 F. 3d 631 (9th Cir. 2005)
  • Smith v. Cutter Biological, 770 So. 2d 392 (La. App. 4th Cir. 2000)
  • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1092 (Dist. South Carolina 1997)
  • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1086 (Dist. South Carolina 1997)
  • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1084 (Dist. South Carolina 1997)
  • Ex parte Knight Ridder, Inc., 982 F.Supp. 1080 (Dist. South Carolina 1997)
  • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1071 (Dist. South Carolina 1995)
  • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1060 (Dist. South Carolina 1996)
  • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1056 (Dist. South Carolina 1996)
  • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1052 (Dist. South Carolina 1995)
  • Briefing before Parliament of Canada’s Green Party of Canada about the $289M Monsanto Roundup cancer verdict and the Monsanto Papers at Parliament Hill, Ottawa, January 30, 2019
  • European Parliament’s Special Committee Hearing on the EU’s authorization procedure for pesticides (PEST), Public Hearing on” Environmental Impacts of Pesticides, including Mitigation Measures at Member State Level” and “Stakeholders Recommendations on the Current EU Regulation on the Approval of PPP” at Brussels, Belgium, September 6, 2018
  • Keynote address to European Green Party, Greens Complimentary Hearing on Pesticides on the consequential effects that pesticides have on human health and the environment at Brussels, Belgium, September 5, 2018
  • Taiwan’s Ministry of Health emergency meeting regarding hemophilia HIV contaminated medication, February 18, 2004

Among his many achievements, accomplished with the help of his team, Michael is most proud of:

  • Chosen by UCLA School of Law as Trial Lawyer for the Year “for his commitment to top-notch advocacy and excellence” and to deliver the 2021 Irving H. Green Memorial Lecture: Suing Monsanto: Corporate Accountability in Trial Law;
  • His firm’s historic $289M and the $2B Roundup cancer verdicts against Monsanto (now Bayer) and the firm's release of The Monsanto Papers;
  • Being recognized, along with his firm, as a national leader in the antidepressant Paxil, Prozac, and Zoloft suicide litigation;
  • Working to bring about the black box suicidality warning for children and young adults, now on most antidepressant labels;
  • Helping spur funding for the Ricky Ray Hemophilia Relief Fund Act of 1998, which was made part of the negotiated settlement to help scores of hemophiliacs infected with HIV by contaminated medication;
  • Arranging for the face-to-face presentation between pharmaceutical company executives and dozens of hemophiliac families that got to say, person by person, holding before and after photos of themselves or departed loved ones, how the hemophilia-AIDS epidemic, and the manner in which the companies caused and covered it up, impacted their lives;
  • Being one of the leaders in the fight against federal preemption, a doctrine pushed by the pharmaceutical industry to wipe out consumers’ rights to sue drug companies for injuries caused by their drugs (Preemption was finally defeated in 2009 with the Supreme Court’s ruling in Wyeth v. Levine);
  • Creating the first class action ever filed against an SSRI-antidepressant manufacturer, ending with the successful resolution of more than 3,000 Paxil injury cases;
  • Finding “needles in haystacks” and “smoking guns” in document productions, such as GE engineers’ graphs predicting the next DC 10 engine failure which mirrored the date of the United 232 crash five years later, an internal study linking SSRIs to cardio birth defects, or documentation of company programs to ghostwrite medical journal articles for academic opinion leaders to give the appearance of objective science when actually serving marketing objectives to increase prescriptions, i.e. disguised advertising;
  • Negotiating the first official public apology by an airline for the 2003 Air Midwest Flt. 5481 Charlotte, North Carolina crash;
  • Eliminating California law that protected tobacco companies from lawsuits. For many years, the statute of limitations was considered to begin to run from the date the plaintiff knew or should have known that he/she was addicted to tobacco. This effectively barred plaintiffs, many of whom began smoking in their teens, from suing. Now, the statute of limitations runs when the plaintiff’s physical injuries are (or reasonably could be) discovered;
  • Developing a rigorous, skillful, and technical method for locating hard-to-find manufacturer documents in order to successfully litigate against major pharmaceutical companies, positioning his firm as a leader in the fight to increase public health and safety;
  • Creating coalitions of activists, attorneys, and Wisner Baum staff, who work together to resolve global problems caused by harmful and defective drugs, which no individual could accomplish alone.

“We have adopted Margaret Mead’s philosophy, ‘Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.’”

Michael is also listed in The Best Lawyers in America®, Southern California Super Lawyers®, the Lawdragon 500 Leading Plaintiff Consumer Lawyers, and The National Trial Lawyers Top 100. Michael also maintains the highest AV® Preeminent Peer Review Rating through Martindale Hubbell® and the highest Avvo.com Superb Score.

"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"

Mary Flores
Reviewed
on Google
Read More Reviews
When companies choose profit over people, we fight. Wisner Baum exposes injustice, demands accountability, and delivers real results for real people. Your Path to Justice Starts Here.
Los Angeles
11111 Santa Monica
Blvd Suite 1750
Los Angeles, CA 90025
Get Directions
Bay Area
100 Drakes Landing Road
Suite 160
Greenbrae, CA 94904
Get Directions
Washington, D.C.
2101 L St NW 

Suite 800
Washington, DC 20037
Get Directions
The information on this website is for general information purposes only. Nothing on this site should be taken as advice for any individual case or situation. This information is not intended to create, and receipt or viewing does not constitute a client relationship.
Send Us Your Case Details
We’ll respond and let you know the best way to proceed with your case.
crossarrow-up
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram